1. Growth hormone therapy for non–islet cell tumor hypoglycemia
Letícia F.G Silveira, MD, Pierre M.G Bouloux, MD, Gavin S MacColl, PhD, Cecilia Camacho-Hubner, MD, PhD, Farideh Miraki-Moud, PhD 
The American Journal of Medicine 
Volume 113, Issue 3, Pages (August 2002)
DOI: /S (02)

2. Figure
Identification of insulin-like growth factor hormone (IGF)-II and pro–IGF-II in the patient’s serum. Elution profiles of immunoreactive IGF-II of serum from the patient and from a normal human serum pool (NHSP) are shown. Samples were analyzed by gel filtration chromatography under acid conditions followed by an IGF-II radioimmunoassay with no cross-reactivity with IGF-I, insulin, or proinsulin. The elution position of radiolabeled rhIGF-II used as a marker is indicated. Increased amounts of pro–IGF-II (approximately 15 kDa; left-hand peak) can be seen in the patient’s serum.
The American Journal of Medicine  , DOI: ( /S (02) )